Auour Investments’s Atea Pharmaceuticals AVIR Stock Holding History

Auour Investments’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$823K	Hold	177,000	–	–	0.24%	45
2026 Q1	$952K	Hold	177,000	–	–	0.3%	45
2025 Q4	$632K	Hold	177,000	–	–	0.2%	52
2025 Q3	$513K	Hold	177,000	–	–	0.17%	52
2025 Q2	$637K	Hold	177,000	–	–	0.22%	47
2025 Q1	$522K	Hold	177,000	–	–	0.19%	49
2024 Q4	$542K	Hold	177,000	–	–	0.19%	50
2024 Q3	$600K	Hold	177,000	–	–	0.21%	49
2024 Q2	$586K	Hold	177,000	–	–	0.22%	48
2024 Q1	$715K	Hold	177,000	–	–	0.26%	48
2023 Q4	$671K	Hold	177,000	–	–	0.26%	46
2023 Q3	$535K	Hold	177,000	–	–	0.23%	46
2023 Q2	$662K	Buy	+177,000	New	+$663K	0.28%	45

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Auour Investments's AVIR Position: Q2 2026 in Review

Auour Investments held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 177,000 shares worth $823K. The position accounts for 0.24% of the portfolio, ranked #45.

Auour Investments first reported a position in AVIR in Q2 2023 and has held it in 13 quarters since. The position peaked at $952K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Auour Investments held 177,000 shares of Atea Pharmaceuticals worth $823K as of Q2 2026.
Auour Investments left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up 0.24% of Auour Investments's portfolio in Q2 2026, its #45 holding.
Auour Investments first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Auour Investments's Atea Pharmaceuticals position peaked at $952K in Q1 2026.
124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Auour Investments's 13F filing for Q2 2026, filed 21 Jul 2026.